Revolutionizing the Metastatic Breast Cancer (mBC) Market Landscape

The Challenge

A mid-sized pharmaceutical client in oncology sought to analyze the metastatic breast cancer (mBC) market but struggled with undefined business rules. Their goal was to assess market size, share across lines of therapy (LOT), days on therapy (DOT), and treatment regimens, and build a robust mBC dashboard for strategic decision-making.

ProcDNA's Solution

Integrated Data Exploration

Leveraged patient-level data (APLD) and NSP data to capture raw market size and share, providing a foundation for accurate market trend projections.

Custom Patient Universe Creation

Developed a relevant mBC patient universe with tailored business rules for BC/HR+/HER2- populations, ensuring accurate insights and market representation.

Advanced Analytics

Analyzed market size, share, and LOT performance, treatment duration (DOT) by regimen, and source of business (SOB), providing deeper insights into therapy adoption and competitive dynamics.

Ad-hoc Analytics

Delivered comprehensive payer-mix and competitive landscape analysis, aligning client strategies with the latest market trends.

Impact

Actionable Insights

Developed a dynamic mBC Market Dashboard, enabling real-time visibility for faster decision-making.

Enhanced Strategy

Empowered the client with precise go-to-market planning and patient adoption forecasting.

Market Leadership

Refined commercial strategies, enhancing competitive advantage in the oncology market.